- Home
- CLB vs LENZ Comparison
CLB vs LENZ Comparison
Compare CLB & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLB
- LENZ
- Stock Information
- Founded
- CLB 1936
- LENZ 2019
- Country
- CLB United States
- LENZ United States
- Employees
- CLB N/A
- LENZ N/A
- Industry
- CLB
- LENZ Medicinal Chemicals and Botanical Products
- Sector
- CLB
- LENZ Health Care
- Exchange
- CLB Nasdaq
- LENZ Nasdaq
- Market Cap
- CLB 951.4M
- LENZ 886.2M
- IPO Year
- CLB 1995
- LENZ 2021
- Fundamental
- Price
- CLB $19.50
- LENZ $33.20
- Analyst Decision
- CLB Sell
- LENZ Strong Buy
- Analyst Count
- CLB 4
- LENZ 6
- Target Price
- CLB $17.00
- LENZ $35.40
- AVG Volume (30 Days)
- CLB 344.3K
- LENZ 185.6K
- Earning Date
- CLB 10-23-2024
- LENZ 11-06-2024
- Dividend Yield
- CLB 0.20%
- LENZ N/A
- EPS Growth
- CLB N/A
- LENZ N/A
- EPS
- CLB 0.54
- LENZ N/A
- Revenue
- CLB $522,821,000.00
- LENZ N/A
- Revenue This Year
- CLB $4.59
- LENZ N/A
- Revenue Next Year
- CLB $5.11
- LENZ N/A
- P/E Ratio
- CLB $36.15
- LENZ N/A
- Revenue Growth
- CLB 2.68
- LENZ N/A
- 52 Week Low
- CLB $13.82
- LENZ $2.12
- 52 Week High
- CLB $25.13
- LENZ $38.93
- Technical
- Relative Strength Index (RSI)
- CLB 49.03
- LENZ 60.99
- Support Level
- CLB $20.41
- LENZ $28.07
- Resistance Level
- CLB $21.65
- LENZ $38.93
- Average True Range (ATR)
- CLB 0.73
- LENZ 2.64
- MACD
- CLB -0.01
- LENZ 0.36
- Stochastic Oscillator
- CLB 24.45
- LENZ 55.27
About CLB Core Laboratories Inc.
Core Laboratories is the premier provider of reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
About LENZ LENZ Therapeutics Inc. Common Stock
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.